Anlotinib is a multi-target tyrosinase inhibitor that blocks tumor angiogenesis by inhibiting VEGFR/FGFR/PDGFR and can also restrain tumor cell proliferation by blockade of FGFR/c-KIT20,21,27. This evidence concerns the gene TYR and neoplasm.